Vieira Cláudia, Borges Andreia, Pereira Filipa F, Antunes Pedro, Redondo Patrícia, Antunes Luís, Lopes José M, Gonçalves Francisco R, Borges Marina, Bento Maria J
Medical Oncology Department, Instituto Português de Oncologia do Porto, Porto, Portugal.
Molecular Oncology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
J Immunother Precis Oncol. 2022 Dec 13;6(1):1-9. doi: 10.36401/JIPO-22-12. eCollection 2023 Feb.
This study aims to assess safety and effectiveness of pertuzumab in combination with trastuzumab and docetaxel in the neoadjuvant treatment (NeoT) of HER2-positive breast cancer.
Two consecutive retrospective cohorts ( = 94, 2012-2015 and 2015-2017) of adult women with HER2-positive breast cancer, receiving NeoT at the breast clinic in Portugal (IPO-Porto), were followed. All patients had surgery and received trastuzumab as adjuvant therapy. The 2012-2015 cohort received doxorubicin, cyclophosphamide, docetaxel plus trastuzumab, whereas the 2015-2017 cohort was treated with the same protocol plus pertuzumab.
The 2012-2015 cohort was older (median 53 years), with locally advanced tumors (48.1%), mostly hormone receptor positive (59.3%). The 2015-2017 cohort was younger (median 43 years) with 60% operable tumors. Pathologic complete response (pCR) improved in the second cohort, while maintaining a good safety profile and tolerability. Clinical staging ( = 0.001) and hormone receptor ( = 0.003) were significant predictors of pCR, but not treatment regimen ( = 0.304).
Further research with larger samples and longer follow-up is needed to understand the clinical differences. Clinical effectiveness of treatment should also be measured through overall and progression-free survival.
本研究旨在评估帕妥珠单抗联合曲妥珠单抗和多西他赛在人表皮生长因子受体2（HER2）阳性乳腺癌新辅助治疗（NeoT）中的安全性和有效性。
对在葡萄牙波尔图肿瘤研究所（IPO - Porto）乳腺科接受新辅助治疗的成年HER2阳性乳腺癌女性患者进行了两个连续的回顾性队列研究（n = 94，2012 - 2015年组和2015 - 2017年组）。所有患者均接受了手术，并接受曲妥珠单抗作为辅助治疗。2012 - 2015年队列接受多柔比星、环磷酰胺、多西他赛加曲妥珠单抗治疗，而2015 - 2017年队列采用相同方案加帕妥珠单抗治疗。
2012 - 2015年队列患者年龄较大（中位年龄53岁），局部晚期肿瘤患者比例较高（48.1%），大多数为激素受体阳性（59.3%）。2015 - 2017年队列患者年龄较小（中位年龄43岁），60%为可手术肿瘤。第二队列的病理完全缓解（pCR）有所改善，同时保持了良好的安全性和耐受性。临床分期（P = 0.001）和激素受体（P = 0.003）是pCR的显著预测因素，但治疗方案不是（P = 0.304）。
需要进行更大样本量和更长随访时间的进一步研究以了解临床差异。还应通过总生存期和无进展生存期来衡量治疗的临床有效性。
